Lineage Net Income Applicable To Common Shares from 2010 to 2026
| LCTX Stock | USD 1.76 -0.09 -4.86% |
Net Loss | First Reported 2014-03-31 | Previous Quarter -4.4 M | Current Value -5.2 M | Quarterly Volatility 21.2 M |
This statements view for Lineage Cell organizes long-term performance signals with capital structure context. The series highlights drivers like Depreciation And Amortization of 664 K, Interest Expense of 6.3 M or Total Revenue of 15.3 M and ratios such as Price To Sales Ratio of 25.08, Dividend Yield of 0.0015 or PTB Ratio of 9.06, complementing Lineage Cell Valuation and Volatility.
Lineage | Net Income Applicable To Common Shares | Build AI portfolio with Lineage Stock |
Analyzing Lineage Cell's Net Income Applicable To Common Shares over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income Applicable To Common Shares has evolved provides context for assessing Lineage Cell's current valuation and future prospects.
Latest Lineage Cell's Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Lineage Cell Therapeutics over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Lineage Cell's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lineage Cell's overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Lineage Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | -29,880,260 | |
| Geometric Mean | 31,853,400 | |
| Coefficient Of Variation | -65.61 | |
| Mean Deviation | 13,127,155 | |
| Median | -31,724,647 | |
| Standard Deviation | 19,604,903 | |
| Sample Variance | 384.4T | |
| Range | 81M | |
| R-Value | 0.21 | |
| Mean Square Error | 391T | |
| R-Squared | 0.05 | |
| Significance | 0.41 | |
| Slope | 834,666 | |
| Total Sum of Squares | 6149.6T |
Lineage Net Income Applicable To Common Shares History
How Much Is Lineage Cell Worth?
Lineage Cell is a small-cap equity in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care categories. Cycle exposure impacts valuation range. We evaluate Lineage Cell through the lens of long-term portfolio construction and diversification efficiency.
Methodology
Unless otherwise specified, financial data for Lineage Cell Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Lineage (USA Stocks:LCTX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Valuation estimates and intrinsic-value models use inputs from public financial disclosures and may not represent market consensus.
Assumptions
The dataset for Lineage Cell Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
Lineage Cell Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for Lineage Stock Analysis
A structured review of Lineage Cell Therapeutics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Lineage Cell Therapeutics Stock. Highlighted below are reports that provide context for Lineage Cell Therapeutics Stock:Compare Lineage Cell against competitors using Lineage Cell Correlation. This supports competitive context. Analysis related to Lineage Cell should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Earnings Share -0.29 | Revenue Per Share | Quarterly Revenue Growth 1.304 | Return On Assets | Return On Equity |
Investors evaluate Lineage Cell Therapeutics using market value and book value, each describing different facets of the business. Intrinsic value is an estimate of what Lineage Cell's fundamentals imply, and it may differ from market and book figures. External forces such as sentiment and macro conditions can shift prices away from fundamental signals. Analytical frameworks help compare those viewpoints.
Value and price for Lineage Cell are related but not identical, and they can diverge across cycles. Evaluation typically reviews profitability, growth, balance sheet strength, industry position, and market signals. By contrast, market price reflects the level where buyers and sellers transact.